Elanco Animal Health (ELAN) Non-Current Assets (2017 - 2026)
Elanco Animal Health's (ELAN) quarterly Non-Current Assets came in at $9.6 billion in Q1 2026, up 1.44% year-on-year from $9.5 billion in Q1 2025, and down 2.65% quarter-over-quarter from $9.9 billion in Q4 2025.
Elanco Animal Health (ELAN) Non-Current Assets (2017 - 2026) Analysis & Trends
Elanco Animal Health has disclosed Non-Current Assets across 10 years of filings, most recently posting $9.6 billion for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $9.6 billion, up 1.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.7 billion (up 2.99% YoY), and the FY2025 annual result was $9.9 billion, up 5.33% from the prior year.
- Non-Current Assets came in at $9.6 billion for Q1 2026 at Elanco Animal Health, down from $9.9 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $13.1 billion in Q1 2022 to a low of $9.4 billion in Q4 2024.
- The 5-year median for Non-Current Assets is $10.1 billion (2025), against an average of $10.8 billion.
- Across the five-year window, Non-Current Assets retreated 19.69% in 2024 and climbed 5.33% in 2025, its largest moves.
- Elanco Animal Health's Non-Current Assets stood at $12.2 billion in 2022, then slipped by 10.29% to $11.0 billion in 2023, then declined by 14.2% to $9.4 billion in 2024, then increased by 5.33% to $9.9 billion in 2025, then dropped by 2.65% to $9.6 billion in 2026.
- The last three Non-Current Assets figures came in at $9.6 billion (Q1 2026), $9.9 billion (Q4 2025), and $10.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 26.33 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 8.68 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 3.84 Bn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 2.47 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 9.64 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.90 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.40 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.22 Bn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 68.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.64 Bn |
| Dec 31, 2025 | 9.90 Bn |
| Sep 30, 2025 | 10.06 Bn |
| Jun 30, 2025 | 10.13 Bn |
| Mar 31, 2025 | 9.50 Bn |
| Dec 31, 2024 | 9.40 Bn |
| Sep 30, 2024 | 9.92 Bn |
| Jun 30, 2024 | 9.75 Bn |
| Mar 31, 2024 | 9.97 Bn |
| Dec 31, 2023 | 10.96 Bn |
| Sep 30, 2023 | 10.78 Bn |
| Jun 30, 2023 | 12.14 Bn |
| Mar 31, 2023 | 12.22 Bn |
| Dec 31, 2022 | 12.21 Bn |
| Sep 30, 2022 | 11.79 Bn |
| Jun 30, 2022 | 12.29 Bn |
| Mar 31, 2022 | 13.06 Bn |
| Dec 31, 2021 | 13.20 Bn |
| Sep 30, 2021 | 13.41 Bn |
| Jun 30, 2021 | 13.40 Bn |